<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02686372</url>
  </required_header>
  <id_info>
    <org_study_id>LTCR-HCC-I-1</org_study_id>
    <nct_id>NCT02686372</nct_id>
  </id_info>
  <brief_title>TCR-Redirected T Cell Infusions to Prevent Hepatocellular Carcinoma Recurrence Post Liver Transplantation</brief_title>
  <official_title>Phase I Study of T Cell Receptor-Redirected T Cells Infusions for Preventing Hepatocellular Carcinoma Recurrence in Patients With HBV-Related Disease Post Liver Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lion TCR Pte. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>First Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Agency for Science, Technology and Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Lion TCR Pte. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hepatocellular Carcinoma (HCC) recurrence rate is high among liver transplant patients, while
      treatment measures are limited. This study plans to recruit 10 subjects with Hepatitis B
      virus (HBV) related HCC after liver transplantation. The objective of the study is to assess
      the safety, tolerability and effectiveness of the HBV specific T cell receptor (HBV/TCR)
      redirected T cell in the target population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A single armed and open labelled trial in patients with hepatocellular carcinoma and HBV
      infection (HBsAg+) post liver transplantation. For patients who successfully match TCR
      histocompatibility locus antigen (HLA) restriction, escalating doses of HBV/TCR expressing
      autologous T cells will be infused. Tests will be done to confirmed safety and efficacy
      during the two-month treatment and observation period and twice each year of a follow up
      period up to five years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of the TCR treatment (according to CTCAE 4.0)</measure>
    <time_frame>Baseline until one month after last treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of induction of tumor specific T cell responses as measured by the persistence of HBV specific T cells in peripheral blood samples at several time points following adoptive transfer</measure>
    <time_frame>Baseline until release from hospital, about 2 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Systemic release of inflammatory cytokines after administration of transduced T cells compared to baseline</measure>
    <time_frame>Baseline until release from hospital, about 2 weeks</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>HBV/TCR-T cell</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Biological: HBV antigen specific TCR redirected T cell infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Biological: HBV antigen specific TCR redirected T cell</intervention_name>
    <description>Subjects will receive escalating doses of HBV antigen specific TCR redirected T cell infusion.</description>
    <arm_group_label>HBV/TCR-T cell</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis as hepatocellular carcinoma (HCC)

          -  Underwent liver transplantation

          -  Seropositive for hepatitis B surface antigen before liver transplantation

          -  No major post-operative complication

          -  Life expectancy of at least 12 weeks

          -  Ability to provide informed consent

          -  Ability to comply with study procedures

          -  Patients with reproductive potential must agree to use an approved contraceptive
             method, and are tested negative for serum or urine pregnancy test result within 14
             days prior to enrolment.

        Exclusion Criteria:

          -  Administration of any other cell therapy, including NK, CIK, DC, CTL, CAR-T, stem
             cells or combined therapy of the kind within 3 months prior to enrolment

          -  Second primary malignancy that is clinically detectable at the time of consideration
             for study enrolment

          -  Likelihood to require steroid treatment during the period of the clinical trial

          -  HLA profile not matching with HLA-class I restriction element of the available T cell
             receptors

          -  Any other concurrent liver infections such as hepatitis A, C or D infection

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, including
             human immunodeficiency virus (HIV) infection

          -  Known Central Nervous System tumours including metastatic brain disease.

          -  Any condition that is unstable or which could jeopardise the safety of the patient and
             his/her compliance in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaoshun He, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Affiliated Hospital, Sun Yat-Sen University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antonio Bertoletti, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Duke-NUS Graduate Medical School</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lietao Li, MD</last_name>
    <phone>(65) 6224 6157</phone>
    <email>clinicaltrials@liontcr.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affiliated Hospital, Sun-Yat Sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoshun He, MD</last_name>
      <phone>(86) 020-8730-6082</phone>
      <email>gdtrc@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Qiang Zhao, Ph.D</last_name>
      <phone>(86) 159-8919-6835</phone>
      <email>522511042@qq.com</email>
    </contact_backup>
    <investigator>
      <last_name>Xiaoshun He, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Qasim W, Brunetto M, Gehring AJ, Xue SA, Schurich A, Khakpoor A, Zhan H, Ciccorossi P, Gilmour K, Cavallone D, Moriconi F, Farzhenah F, Mazzoni A, Chan L, Morris E, Thrasher A, Maini MK, Bonino F, Stauss H, Bertoletti A. Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient. J Hepatol. 2015 Feb;62(2):486-91. doi: 10.1016/j.jhep.2014.10.001. Epub 2014 Oct 13.</citation>
    <PMID>25308176</PMID>
  </reference>
  <reference>
    <citation>Gehring AJ, Xue SA, Ho ZZ, Teoh D, Ruedl C, Chia A, Koh S, Lim SG, Maini MK, Stauss H, Bertoletti A. Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines. J Hepatol. 2011 Jul;55(1):103-10. doi: 10.1016/j.jhep.2010.10.025. Epub 2010 Nov 23.</citation>
    <PMID>21145860</PMID>
  </reference>
  <reference>
    <citation>Koh S, Shimasaki N, Suwanarusk R, Ho ZZ, Chia A, Banu N, Howland SW, Ong AS, Gehring AJ, Stauss H, Renia L, SÃ¤llberg M, Campana D, Bertoletti A. A practical approach to immunotherapy of hepatocellular carcinoma using T cells redirected against hepatitis B virus. Mol Ther Nucleic Acids. 2013 Aug 13;2:e114. doi: 10.1038/mtna.2013.43.</citation>
    <PMID>23941866</PMID>
  </reference>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 17, 2016</study_first_submitted>
  <study_first_submitted_qc>February 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2016</study_first_posted>
  <last_update_submitted>March 21, 2016</last_update_submitted>
  <last_update_submitted_qc>March 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hepatocellular carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

